LTUS OTC
Lotus Pharmaceuticals, Inc.
1W: +8.4%
1M: +46.3%
3M: +41.6%
YTD: +46.3%
1Y: +29.1%
3Y: -26.8%
5Y: -87.8%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$29K
-108.4% ▼
Net Income
-$29K
-126.2% ▼
EPS (Diluted)
$0.00
+0.0% ▲
EBITDA
-$29K
-126.2% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $30K | $21K | $19K | $14K | $29K |
| Operating Expenses | $30K | $21K | $19K | $14K | $29K |
| Operating Income | -$30K | -$21K | -$19K | -$14K | -$29K |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$30K | -$21K | -$19K | $111K | -$29K |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$30K | -$21K | -$19K | $111K | -$29K |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EBITDA | -$30K | -$21K | -$19K | $111K | -$29K |
| Shares Outstanding | 2.94B | 2.69B | 2.69B | 2.69B | 2.69B |